Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03651076 · ClinicalTrials.gov registry record · NA
Traxi Panniculus Retractor for Cesarean Delivery
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 142
- Enrollment target
NCT03651076: Clinical Trial NA study, sponsored by Beth Israel Deaconess Medical Center.
NCT03651076 is a NA study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 142 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03651076, a NA study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 142 participants
- Enrollment target
Study Summary
This prospective, open-label, randomized-controlled trial is designed to evaluate the use of the Traxi panniculus retractor-- a commercially available Class I FDA-exempt device will improve surgical outcomes, cardiopulmonary function, and provider/patient satisfaction in morbidly obese women undergoing cesarean delivery.
Primary Outcome
time from skin incision to closure during cesarean delivery
Interventions
- DEVICE Traxi panniculus retraction (Clinical Innovations, LLC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2018-10-02 |
| Est. Completion | 2025-02-01 |
| Phase | NA |
Why NCT03651076 stopped before completion
NCT03651076 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Traxi panniculus retraction (Clinical Innovations, LLC) is the first listed.
NCT03651076 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03651076 about?
NCT03651076 is a clinical study titled "Traxi Panniculus Retractor for Cesarean Delivery". This prospective, open-label, randomized-controlled trial is designed to evaluate the use of the Traxi panniculus retractor-- a commercially available Class I FDA-exempt device will improve surgical outcomes, cardiopulmonary function, and provider/patient satisfaction in morbidly obese women undergo...
What is the current status of trial NCT03651076?
This trial is currently terminated. It is a NA study. The enrollment target is 142 participants. The study started on 2018-10-02. Estimated completion is 2025-02-01.
What interventions are being tested in trial NCT03651076?
The interventions under investigation include: Traxi panniculus retraction (Clinical Innovations, LLC) (DEVICE).
Who is sponsoring clinical trial NCT03651076?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03651076's enrollment target sits among peer trials
142 711th of 2000 higher than 1,289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI